All lobbying filings

Avenue Solutions

Avenue Solutions filed a Q3 report for Incyte Corporation on October 20, 2026, reporting $60,000 in lobbying income.

Lobbying for Incyte Corporation · Biopharmaceutical company

As filed: AVENUE SOLUTIONS for INCYTE CORPORATION.

All filings by Avenue Solutions · Everything Incyte Corporation has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Income

$60,000

What the client paid this registrant for the period.

Client based in

Delaware

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Health Issues

Issues related to 340B

Medicare/Medicaid

Issues related to Medicaid rebates; Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to CMMI demos (Guarding U.S. Medicare Against Rising Drug Costs (GUARD) and Global Benchmark for Efficient Drug Pricing (GLOBE)); Issues related to Senate Finance Dear Colleague process; Education around access to innovative therapies in dermatology; Issues related to the Orphan Cures Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.